Reckitt Benckiser Group (RKT) Barclays 19th Annual Global Consumer Conference summary

Litigation and legal developments

• Achieved a unanimous win in MDL litigation, reinforcing confidence in legal strategy and outcomes across multiple jurisdictions.

• No near-term cases are scheduled, but management remains pragmatic and open to practical resolutions for shareholders.

Mead Johnson business and strategic options

• Mead Johnson is performing well, especially in emerging markets, with strong brands and market share gains.

• Significant investments are being made in supply, brands, and innovation, attracting broad inbound interest.

• All strategic options for Mead Johnson are under consideration, though no formal process is underway.

• Management is focused on achieving good value for the asset and will be pragmatic in any exit.

Cold, flu, and upper respiratory trends

• Last year’s cold and flu season was weak, but current sell-in for upper respiratory products in North America is at a seven-year high.

• Retailers are highly engaged, and new product launches like 12HR Cold & Flu are driving excitement.

• Management sees no evidence that GLP-1 drugs or improved flu vaccines are negatively impacting the category.